Stenotrophomonas maltophilia in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance
Infection and Drug Resistance · 2026-08 · Volume 19 · 1-17
DOI: 10.2147/idr.s627852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection and Drug Resistance, 2026-08. Verfasst von Rong Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou, Jiangsu, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Stenotrophomonas maltophilia is a globally distributed, aerobic, non-fermenting Gram-negative bacillus increasingly recognized as an opportunistic pathogen in hospitalized and immunocompromised patients. Clinical interpretation is challenging because respiratory and device-associated isolates may represent colonization, polymicrobial infection, or true invasive disease. Recent genomic studies further suggest that organisms historically identified as S. maltophilia comprise a genetically diverse species complex, with implications for epidemiology, virulence, resistance surveillance, and susceptibility testing. Treatment is difficult because of biofilm formation, persistence in water-associated healthcare reservoirs, and intrinsic or acquired resistance mediated by L1 and L2 β-lactamases, multidrug efflux pumps, reduced permeability, mobile resistance determinants, and biofilm-associated tolerance. Current IDSA guidance identifies cefiderocol monotherapy as the preferred treatment for invasive S. maltophilia infection, whereas aztreonam-avibactam and agents such as trimethoprim-sulfamethoxazole, levofloxacin, and minocycline occupy alternative or combination-based roles. Nevertheless, the therapeutic evidence base remains uneven, and clinical decisions should integrate infection severity, source control, susceptibility findings, pharmacokinetic/pharmacodynamic (PK/PD) exposure, toxicity, infection site, and host-related factors. This review summarizes advances in taxonomy, epidemiology, pathogenesis, diagnostics, resistance, treatment, infection prevention, and genomic surveillance, and highlights the need for standardized identification, validated breakpoints, prospective comparative-effectiveness studies, and pragmatic or adaptive trial designs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou, Jiangsu, People's Republic of China.
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
Zitieren
APA
Sun, R., Cao, X., & Sun, Q. (2026). Stenotrophomonas maltophilia in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance. Infection and Drug Resistance, Volume 19, 1-17. https://doi.org/10.2147/idr.s627852
Vancouver
Sun R, Cao X, Sun Q. Stenotrophomonas maltophilia in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance. Infection and Drug Resistance. 2026;Volume 19:1-17. doi:10.2147/idr.s627852
BibTeX
@article{Sun2026,
author = {Sun, Rong and Cao, Xiaoli and Sun, Qianjin},
title = {Stenotrophomonas maltophilia in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--17},
doi = {10.2147/idr.s627852}
}
EUVIMED